These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38429922)

  • 21. A multi-center safety trial of the oral iron chelator deferiprone.
    Cohen A; Galanello R; Piga A; Vullo C; Tricta F
    Ann N Y Acad Sci; 1998 Jun; 850():223-6. PubMed ID: 9668543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deferiprone-induced agranulocytosis: 20 years of clinical observations.
    Tricta F; Uetrecht J; Galanello R; Connelly J; Rozova A; Spino M; Palmblad J
    Am J Hematol; 2016 Oct; 91(10):1026-31. PubMed ID: 27415835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial.
    Elalfy MS; Adly A; Awad H; Tarif Salam M; Berdoukas V; Tricta F
    Am J Hematol; 2018 Feb; 93(2):262-268. PubMed ID: 29119631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
    Olivieri NF; Sabouhanian A; Gallie BL
    PLoS One; 2019; 14(2):e0211942. PubMed ID: 30811439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study.
    Botzenhardt S; Felisi M; Bonifazi D; Del Vecchio GC; Putti MC; Kattamis A; Ceci A; Wong ICK; Neubert A;
    Haematologica; 2018 Jan; 103(1):e1-e4. PubMed ID: 29079595
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload.
    Binding A; Ward R; Tomlinson G; Kuo KHM
    Eur J Haematol; 2019 Aug; 103(2):80-87. PubMed ID: 31066943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
    Calvaruso G; Vitrano A; Di Maggio R; Ballas S; Steinberg MH; Rigano P; Sacco M; Telfer P; Renda D; Barone R; Maggio A;
    Blood Cells Mol Dis; 2014 Dec; 53(4):265-71. PubMed ID: 24814618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes.
    Shah R; Shah A; Badawy SM
    Expert Rev Hematol; 2023 Feb; 16(2):81-94. PubMed ID: 36755516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Long-Term Efficacy of Deferiprone in Thalassemia Patients With Iron Overload: Real-World Data from the Registry Database.
    Kittipoom T; Tantiworawit A; Punnachet T; Hantrakun N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Norasetthada L; Fanhchaksai K; Charoenkwan P
    Hemoglobin; 2022 Mar; 46(2):75-80. PubMed ID: 35982534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Yearly Cost Related to Complications Between Deferasirox and Deferiprone Monotherapy in Thalassemia.
    Sari TT; Wahidiyat PA; Rahmartani LD; Iskandar SD; Putri IA
    J Pediatr Hematol Oncol; 2024 Aug; 46(6):e402-e405. PubMed ID: 38832436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia.
    Jamuar SS; Lai AH; Tan AM; Chan MY; Tan ES; Ng IS
    J Paediatr Child Health; 2011 Nov; 47(11):812-7. PubMed ID: 21902752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deferiprone as an oral iron chelator in sickle cell disease.
    Voskaridou E; Douskou M; Terpos E; Stamoulakatou A; Meletis J; Ourailidis A; Papassotiriou I; Loukopoulos D
    Ann Hematol; 2005 Jul; 84(7):434-40. PubMed ID: 15809885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
    Kontoghiorghes GJ; Neocleous K; Kolnagou A
    Drug Saf; 2003; 26(8):553-84. PubMed ID: 12825969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M; Borgna-Pignatti C
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
    Cohen AR; Galanello R; Piga A; De Sanctis V; Tricta F
    Blood; 2003 Sep; 102(5):1583-7. PubMed ID: 12763939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term response to deferiprone therapy in Asian Indians.
    Panigrahi I; Marwaha RK; Das RR
    Ann Hematol; 2010 Feb; 89(2):135-40. PubMed ID: 19655143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
    Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.
    Botzenhardt S; Sing CW; Wong IC; Chan GC; Wong LY; Felisi M; Rascher W; Ceci A; Neubert A
    Curr Drug Saf; 2016; 11(2):137-44. PubMed ID: 26419768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.
    Cancado R; Olivato MC; Bruniera P; Szarf G; de Moraes Bastos R; Rezende Melo M; Chiattone C
    Acta Haematol; 2012; 128(2):113-8. PubMed ID: 22760067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.